Great questions regarding FDA decision making process. For better or worse, at least we should expect FDA to show consistency. The current tsunami of China-only or China-mainly or China-plus submissions is unprecedented, requiring consistency rather than trial by trial decisions.
One of the reasons why @FDA rejected Ivonescimab approval claim is that 93 % events occur in China.View quoted post on X
I have two questions
1- what is the cut off for events to occur in USA for USFDA to consider that data as good enough? Is there a number? 40 % , 50 % , 60 % ?
2 - Guess this trial and tell me how usfda will react to its results ? It has only 39 pts out of 602 ( 6.4 % ) from USA and in pre specified subset analysis they dont do well ( see the graph on right )
Hint - trial got maximum applause at #esmo26 .
The slide is from our upcoming OncoWisdom webinar on 20 th November to discuss esmo26 key data . @Timothee_MD @StephenVLiu @JacobPlieth @KolPulseAI @NeilVasan @JackWestMD